Caricamento...
RANKL Inhibition Improves Bone Properties in a Mouse Model of Osteogenesis Imperfecta
Recently, a new class of agents targeting the receptor activator of nuclear factor-κB ligand (RANKL) pathway has been developed for the treatment of osteoporosis and other bone diseases. In the current study, inhibition of the RANKL pathway was evaluated to assess effects on “bone quality” and fract...
Salvato in:
| Autori principali: | , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2010
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2962883/ https://ncbi.nlm.nih.gov/pubmed/20053133 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/03008200903108472 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|